OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Hill on the Utility of BTK Inhibitors in Relapsed/Refractory MCL

December 2nd 2020

Brian T. Hill, MD, PhD, discusses the utility of BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Dr. Mascarenhas on the Role of Genetic Testing in MPNs

December 2nd 2020

John O. Mascarenhas, MD, discusses the role of genetic testing in myeloproliferative neoplasms.

Dr. Costello on Considerations for Induction Therapy Selection in Multiple Myeloma

December 2nd 2020

Caitlin Costello, MD, discusses considerations for induction therapy selection in multiple myeloma.

Dr. Mesa on the Potential Role of Momelotinib for Myelofibrosis-Associated Anemia

December 1st 2020

Ruben A. Mesa, MD, discusses the potential role of momelotinib in alleviating myelofibrosis-associated anemia.

Dr. Kim on the Evolution of Therapy in Metastatic HCC

December 1st 2020

Joseph Kim, MD, discusses the evolution of therapy in metastatic hepatocellular carcinoma.

Dr. Ghosh on Unmet Needs With CAR T-Cell Therapy in DLBCL

December 1st 2020

Nilanjan Ghosh, MD, PhD, director of the Lymphoma Program and a physician with Levine Cancer Institute, discusses unmet needs with CAR T-cell therapy in diffuse large B-cell lymphoma.

Dr. Agarwal on Unmet Needs in mHSPC

December 1st 2020

Neeraj Agarwal, MD, discusses unmet needs in metastatic hormone-sensitive prostate cancer.

Dr. Weber on the Treatment of LDH-High Melanoma

December 1st 2020

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the melanoma program, Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, NYU Langone Health’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses the treatment of lactate dehydrogenase (LDH)–high melanoma.

Dr. Winter on the Role of Frontline Targeted Therapies in CLL

November 30th 2020

Allison Winter, MD, hematologist/medical oncologist, Cleveland Clinic, discusses the role of frontline targeted therapies in chronic lymphocytic leukemia.

Dr. Nagle on Investigational Cellular Therapies in Multiple Myeloma

November 30th 2020

Sarah Nagle, MD, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses investigational cellular therapies in multiple myeloma.

Dr. Ruan on Treatment Considerations for Relapsed/Refractory MCL

November 30th 2020

Jia Ruan, MD, PhD, associate professor of clinical medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treatment considerations for patients with relapsed/refractory mantle cell lymphoma.

Dr. El Chaer on the Potential for Combination Strategies With Ruxolitinib in MPNs

November 25th 2020

Firas El Chaer, MD, discusses the potential utility of combination strategies with ruxolitinib in patients with myeloproliferative neoplasms.

Dr. Kim on Curative Treatment Options in HCC

November 25th 2020

Joseph Kim, MD, discusses curative therapeutic options in hepatocellular carcinoma.

Dr. Brody on Managing CAR T-Cell Therapy Toxicities in MCL

November 25th 2020

Joshua Brody, MD, discusses management strategies for the toxicities associated with CAR T-cell therapy in mantle cell lymphoma.

Dr. Boutros on the Utility of Genetic Testing in Prostate Cancer

November 24th 2020

Paul C. Boutros, PhD, MBA, discusses the utility of genetic testing in prostate cancer.

Dr. Opyrchal on the Current State of Biomarkers in TNBC

November 24th 2020

Mateusz Opyrchal, MD, PhD, discusses the current state of biomarkers in triple-negative breast cancer.

Dr. Mikhael on Remaining Challenges in High-Risk Multiple Myeloma

November 24th 2020

Joseph Mikhael, MD, discusses remaining challenges in high-risk multiple myeloma.

Dr. Luke the Role of Molecular Testing in Melanoma

November 24th 2020

Jason J. Luke, MD, FACP, discusses the role of molecular testing in melanoma.

Dr. Janjigian on the Importance of First-Line Therapy Selection in Gastric Cancer

November 24th 2020

Yelena Y. Janjigian, MD, discusses the importance of selecting an optimal first-line therapy in gastric cancer.

Dr. Dorritie on Determining Transplant Eligibility in Multiple Myeloma

November 24th 2020

Kathleen A. Dorritie, MD, discusses transplant eligibility in multiple myeloma.